BCR and B-cell chronic lymphocytic leukemia: A separate phase 2 study evaluated venetoclax monotherapy in 127 patients with R/R CLL after B-cell receptor (BCR) inhibitor ibrutinib or idelalisib treatment (M14-032; NCT02141282) (Table 1) and observed ORRs of 65% and 67% in the ibrutinib- and idelalisib-relapsed patients [50,51], delineating venetoclax as a viable therapeutic option after disease progression on BCR inhibitor therapy.